Contrasting BioCryst Pharmaceuticals (NASDAQ:BCRX) & Calidi Biotherapeutics (NYSE:CLDI)

Calidi Biotherapeutics (NYSE:CLDI) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk and analyst recommendations.

Profitability

This table compares Calidi Biotherapeutics and BioCryst Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Calidi Biotherapeutics	N/A	N/A	-219.07%
BioCryst Pharmaceuticals	-38.18%	N/A	-28.14%

Institutional & Insider Ownership

12.5% of Calidi Biotherapeutics shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 24.3% of Calidi Biotherapeutics shares are owned by company insiders. Comparatively, 4.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Calidi Biotherapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Calidi Biotherapeutics and BioCryst Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calidi Biotherapeutics	0	0	3	0	3.00
BioCryst Pharmaceuticals	0	1	5	0	2.83

Calidi Biotherapeutics currently has a consensus target price of $16.67, indicating a potential upside of 1,134.57%. BioCryst Pharmaceuticals has a consensus target price of $14.17, indicating a potential upside of 68.05%. Given Calidi Biotherapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Calidi Biotherapeutics is more favorable than BioCryst Pharmaceuticals.

Earnings and Valuation

This table compares Calidi Biotherapeutics and BioCryst Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calidi Biotherapeutics	$50,000.00	299.97	-$29.22 million	N/A	N/A
BioCryst Pharmaceuticals	$382.24 million	4.56	-$226.54 million	($0.73)	-11.55

Calidi Biotherapeutics has higher earnings, but lower revenue than BioCryst Pharmaceuticals.

Summary

Calidi Biotherapeutics beats BioCryst Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.